Search This Blog

Saturday, July 5, 2014

GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation | 2014 | Press releases | Media | GlaxoSmithKline

GSK receives EU marketing authorisation for Mekinist™ (trametinib) for patients with unresectable or metastatic melanoma with a BRAF V600 mutation | 2014 | Press releases | Media | GlaxoSmithKline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.